9-(2-hydroxy-3-nonyl)adenine has been researched along with cilostamide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Chen, G; Ke, H; Kunz, S; Martinelli, S; Robinson, H; Seebeck, T; Wan, Y; Wang, H | 1 |
| Maurice, DH; Palmer, D; Tsoi, K | 1 |
| Benelli, C; Clot, JP; Desbuquois, B; Fouque, F; Geoffroy, V; Lugnier, C; Nivet, V | 1 |
| Hernández, J; Juan-Fita, MJ; Vargas, ML | 1 |
| Gergs, U; Laufs, U; Neumann, J; Voss, R; Werner, C | 1 |
1 review(s) available for 9-(2-hydroxy-3-nonyl)adenine and cilostamide
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
5 other study(ies) available for 9-(2-hydroxy-3-nonyl)adenine and cilostamide
| Article | Year |
|---|---|
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
Topics: Amino Acid Sequence; Bridged Bicyclo Compounds, Heterocyclic; Catalytic Domain; Conserved Sequence; Crystallography, X-Ray; Drug Design; Kinetics; Molecular Sequence Data; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Binding; Protein Structure, Secondary; Protozoan Proteins; Recombinant Proteins; Saccharomyces cerevisiae; Sulfonamides; Surface Properties; Trypanosoma cruzi | 2012 |
Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenine; Animals; Aorta; Becaplermin; Cell Movement; Cells, Cultured; Colforsin; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Synergism; Humans; Kinetics; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Quinolones; Rats; Recombinant Proteins | 1998 |
Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Endosomes; Enzyme Activation; Enzyme Inhibitors; Golgi Apparatus; Liver; Male; Naphthalenes; Phosphodiesterase Inhibitors; Protein Kinase C; Quinolones; Rats; Rats, Sprague-Dawley; Tetradecanoylphorbol Acetate; Time Factors | 1999 |
The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adrenergic beta-Antagonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Female; Glucagon; Heart Ventricles; Imidazoles; In Vitro Techniques; Male; Myocardial Contraction; Phosphodiesterase I; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Quinolones; Rats; Rats, Sprague-Dawley; Ventricular Function; Xanthines | 2005 |
Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H
Topics: Adenine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Female; Heart Atria; Heart Rate; Histamine; Humans; Male; Mice; Mice, Transgenic; Phosphodiesterase Inhibitors; Quinolones; Receptors, Histamine H2; Rolipram | 2021 |